Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | UQCRB | P14927 | 1/20 | 0.40 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890184 | 0.85 | SLC22A12 (0.59) | SLC22A12ACLY | |
| SCHEMBL4885016 | 0.83 | BRD4 (0.53) | MCL1SLC22A12CYP19A1BRD4IDH1 | |
| SCHEMBL4896085 | 0.83 | SLC22A12 (0.50) | MCL1SLC22A12CYP19A1ACLYBRD4 | |
| SCHEMBL4893186 | 0.82 | SLC22A12 (0.49) | MCL1SLC22A12CYP19A1BRD4IDH1 | |
| SCHEMBL14023341 | 0.80 | SLC22A12 (0.55) | SLC22A12ACLY | |
| SCHEMBL4891619 | 0.78 | KIF11 (0.45) | — | |
| SCHEMBL4890178 | 0.78 | MCL1 (0.47) | MCL1SLC22A12CYP19A1ACLYBRD4 | |
| SCHEMBL29022938 | 0.74 | CA2 (0.61) | — | |
| SCHEMBL14023339 | 0.74 | SLC22A12 (0.48) | SLC22A12ACLY | |
| SCHEMBL14023342 | 0.73 | SLC22A12 (0.55) | SLC22A12ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | claimed |
| EP-1756025-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105712-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | claimed |
| US-20080255240-A1 | Sulfonamide Derivatives | NOVO NORDISK A/S (DK) | 2008-10-16 | — | — | US | disclosed |
| EP-1756025-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005105712-A1 | SULFONAMIDE DERIVATIVES | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255240-A1 | Sulfonamide Derivatives | FABP4, SQOR, CS | MCL1 4068/4885SLC22A12 1558/4885CYP19A1 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.